CORCEPT THERAPEUTICS INCORPORATED Corcept Therapeutics Incorporated announced completion of enrollment in GRADIENT, a Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with Cushing's syndrome (hypercortisolism) caused by an adrenal adenoma or adrenal hyperplasia. GRADIENT is a randomized, double-blind, placebo-controlled trial conducted at sites in the United States, Europe and Israel. One-h hundred thirty-seven patients were randomized 1:1 to receive relacorilant or placebo for 22 weeks.
Primary endpoints are improvement in glucose metabolism and hypertension. GRADIENT is a randomized, double-blind, placebo-controlled trial conducted at sites in the United States, Europe and Israel. One-hundred thirty-seven patients were randomized 1:1 to receive relacorilant or placebo for 22 weeks.
Primary endpoints are improvement in glucose metabolism and hypertension.
